Clinical Trial Detail

NCT ID NCT02074878
Title CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Baylor Breast Care Center
Indications

Her2-receptor negative breast cancer

Therapies

Sunitinib + Crizotinib

Age Groups: adult

Additional content available in CKB BOOST